知识与财富的链接
目的 系统分析应用虚拟现实技术在心血管病患者负性情绪中的效果,为临床实践提供参考。方法 计算机检索The Cochrane Library、PubMed、CINAHL、Web of Science、中国知网、万方、维普、超星和中国生物医学文献数据库中关于应用虚拟现实技术对减轻心血管病患者负性情绪效果的随机对照研究,检索时限为建库至2024年4月6日。由2名研究者独立对纳入的文献进行筛选和数据提取,通过Revman5.4软件对所纳入文献进行Meta分析。结果 共纳入10项研究,共540名心血管病患者。结果显示,虚拟现实技术可显著降低心血管病患者在医院焦虑抑郁量表（HADS）中的焦虑评分［MD=-2.29,95%CI（-3.50,-1.08）,P＜0.001］、压力感知水平（PSQ）评分［MD=-15.29,95%CI（-19.70,-10.87）,P＜0.001］,但对于抑郁评分的改善不显著（P＞0.05）。结论 应用虚拟现实技术可降低心血管病患者焦虑和压力情绪,并在医院焦虑抑郁量表（HADS）中的焦虑评分上显示显著改善。然而,对于改善抑郁症状,结果并未达到显著水平,未来仍需进一步的大样本、高质量研究来验证其效果。
Objective: To systematically analyze the effect of virtual reality technology on negative emotions in patients with cardiovascular diseases and provide references for clinical practice. Methods: Randomized controlled studies on the effect of virtual reality technology in reducing negative emotions in patients with cardiovascular diseases were retrieved from The Cochrane Library, PubMed, CINAHL, Web of Science, CNKI, Wanfang, VIP, Chaoxing, and China Biomedical Literature Database. The search period was from the establishment of the databases to April 6, 2024. Two researchers independently screened and extracted data from the included studies, and a meta-analysis was conducted using Revman 5.4 software. Results: A total of 10 studies involving 540 patients with cardiovascular diseases were included. The results showed that virtual reality technology could significantly reduce the anxiety score in the Hospital Anxiety and Depression Scale (HADS)[MD=-2.29, 95% CI (-3.50, -1.08), P<0.001] and Perceived Stress Questionnaire (PSQ) score [MD=-15.29, 95% CI (-19.70, -10.87), P<0.001]of patients with cardiovascular diseases, but had no significant effect on the depression score (P > 0.05). Conclusion The application of virtual reality technology can reduce anxiety and stress in patients with cardiovascular diseases and show significant improvement in the anxiety score of the Hospital Anxiety and Depression Scale (HADS). However, the results did not reach a significant level for improving depressive symptoms. Further large-sample, high-quality studies are still needed to verify its effect in the future.
